Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
MA-0204
Cat. No.:
0225LY-0930
Appearance:
Solid
Purity:
≥97%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
MA-0204 is an orally bioavailable and highly selective PPARδ modulator (EC50: 0.4 nM for human) being investigated as a potential therapy for Duchenne Muscular Dystrophy (DMD).
Synonym:
2095128-17-7; (R)-3-methyl-6-(2-((5-methyl-2-(4-(trifluoromethoxy)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoic acid; (3R)-3-methyl-6-[2-[[5-methyl-2-[4-(trifluoromethoxy)phenyl]imidazol-1-yl]methyl]phenoxy]hexanoic acid; (3R)-3-methyl-6-[2-({5-methyl-2-[4-(trifluoromethoxy)phenyl]imidazol-1-yl}methyl)phenoxy]hexanoic acid
CAS No.:
2095128-17-7
Compound CID:
126752361
Formula:
C25H27F3N2O4
Formula Weight:
476.49
Specification
Targets&IC50:
PPARδ: 10 nM (EC50)(in rat); PPARδ: 7.9 nM (EC50)(in mouse); PPARδ: 0.4 nM (EC50)(in human)
Relative Density:
1.23 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
MA-0204 can be used in metabolic studies to investigate the therapeutic effects of selective PPAR-delta modulation.
Library Information
Target:
PPAR
Receptor:
PPARδ
Pathways:
Metabolism; DNA damage/DNA repair
Plate Number:
AOCL-12
Plate Location:
h11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
40 mg/mL; 83.95 mM
